下呼吸道治療市場－全球產業規模、佔有率、趨勢、機會及預測（依疾病類型、藥物類別、給藥途徑、最終用戶、地區及競爭格局分類，2021-2031年）

全球呼吸系統藥物市場預計將從 2025 年的 360.5 億美元大幅成長至 2031 年的 589.1 億美元，複合年成長率為 8.53%。

這個市場領域涵蓋用於治療肺部和氣道疾病的藥物，例如抗生素、抗發炎藥物和支氣管擴張劑，這些疾病包括肺炎、慢性阻塞性肺病（COPD）和氣喘。推動這一市場擴張的關鍵因素是需要持續治療的慢性呼吸系統疾病盛行率不斷上升，而全球空氣品質惡化和快速都市化對這一趨勢產生了顯著影響。國際呼吸學會論壇預測，到2024年，每年將有700萬人死於與空氣污染相關的疾病，凸顯了全球對有效肺部治療方法的迫切需求，也凸顯了這個問題的嚴重性。

儘管市場需求強勁，抗菌藥物抗藥性仍是一個重大障礙。這種抗藥性會逐漸削弱標準抗感染療法的療效，導致臨床結果惡化。這迫使製藥公司必須經歷昂貴且複雜的監管流程才能推出新藥。因此，這些挑戰會加重醫療預算負擔，延緩新一代療法的推出，並阻礙整體市場擴張。

市場促進因素

全球慢性呼吸系統疾病負擔日益加重，是推動全球下呼吸道治療市場發展的主要因素。氣喘和慢性阻塞性肺病（COPD）等疾病的盛行率不斷上升，是推動這一市場成長的主要動力。這些疾病需要持續藥物治療來控制症狀並預防病情惡化。根據國際藥學聯盟（FIP）發布的《2024年全球COPD現況報告》，目前全球約有3.91億人患有COPD，龐大的病患群體依賴維持性治療。環境因素進一步加劇了這項需求。美國肺臟協會於2024年4月發布的《空氣污染狀況報告》顯示，美國約有1.31億人居住在顆粒物和臭氧污染水平超標的地區，這直接促使人們對有效的呼吸系統治療藥物產生了迫切需求。

重塑市場的第二個關鍵因素是生物製藥和標靶治療方法的進步。由於傳統支氣管擴張劑往往無法有效治療重症患者，製藥開發商正將重心轉向精準藥物和針對特定發炎路徑的單株抗體。這一轉變促成了高價值生物製藥的成功商業化，並佔據了顯著的市場佔有率。例如，再生元製藥公司在2024年10月發布的2024年第三季財報中報告稱，其旗艦呼吸系統生物製藥Dupixent的全球淨銷售額達到38.2億美元，年增23%。這一強勁的業績凸顯了標靶治療的快速普及及其在推動未來市場收入成長方面的重要作用。

市場挑戰

抗菌素抗藥性持續降低現有抗生素產品的商業性和臨床效用，對全球下呼吸道治療市場的成長構成重大障礙。隨著細菌病原體對標準療法產生抗藥性，藥物的有效壽命顯著縮短，為製藥企業帶來動盪的經營環境。這種生物進化迫使企業持續投資研發新化合物以取代過時藥物，但由於新的抗藥性機制出現迅速，投資回報也難以預測。因此，呼吸道抗感染藥物研發的高風險阻礙了持續的資本投入，並減緩了整體市場擴張。

克服這種阻力的挑戰進一步限制了產品開發平臺的停滯，阻礙了產業成長。檢驗新藥所需的嚴格監管流程既耗時又昂貴，導致缺乏可立即上市的創新產品。根據國際藥品製造商協會聯合會（IFPMA）2024年的數據，全球抗生素研發管線中僅有一種候選藥物處於III期臨床試驗階段，該藥物針對的是衛生當局確定的關鍵優先病原體。後期治療方案的匱乏限制了產業滿足臨床需求的能力，限制了收入潛力，並阻礙了該領域的財務進展。

市場趨勢

數位健康平台與智慧吸入器的整合正在改變患者護理模式，使其從被動治療轉變為主動藥物依從性監測。這些技術利用感測器設備即時追蹤藥物使用情況，並將數據傳輸給醫療服務提供者，以便檢測用藥依從性問題並主動預測病情加重。這個數位生態系統能夠實現及時干預，並為患者提供切實可行的呼吸系統健康訊息，從而顯著改善臨床療效。根據瑞思邁（ResMed）於2024年1月發布的2024會計年度第二季財報電話會議，該公司在上年度透過其雲端軟體和數位健康產品惠及超過1.7億人。這充分展現了連網呼吸技術目前對患者照護產生的巨大影響。

同時，在監管機構要求減少氫氟碳吸入器對環境影響的壓力下，市場正經歷著向永續、低碳推進劑裝置的關鍵轉型。製造商正積極調整產品系列，以環保替代品（例如HFA-152a）取代全球暖化潛勢（GWP）高的推進劑，從而在日益嚴格的環境法規下確保商業性永續性。這項策略轉變既保護了產品生命週期免受高碳氣霧劑潛在法律禁令的影響，也滿足了對環境友善醫療保健解決方案日益成長的需求。根據《製藥技術》雜誌2024年4月報道，凱西製藥公司（Chiesi Farmaceutici）正在投資3.5億歐元開發一種新型吸入器推進劑，預計與2019年相比，該推進劑將使公司範圍3的排放減少90%。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球下呼吸系統藥物市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依疾病類型（氣喘、慢性阻塞性肺病、肺炎、結核病、支氣管炎、其他）
  • 依藥物類別（抗生素、非類固醇消炎劑、止咳藥、鼻減充血劑、其他）
  • 依給藥途徑（口服、腸外、其他）
  • 按最終使用者（醫院/診所、門診護理中心、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美下呼吸道藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲下呼吸道藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區下呼吸道藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲下呼吸道藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

10. 南美洲下呼吸道藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球下呼吸道治療市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• F. Hoffmann-La Roche Ltd.
• Teva Pharmaceutical Industries Ltd.
• Sanofi SA
• Pfizer Inc.
• GSK plc
• Novartis AG
• AstraZeneca inc.
• Johnson & Johnson
• Sun Pharmaceutical Industries Ltd.
• Merck & Co., Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Lower Respiratory Tract Therapeutics Market is projected to experience substantial growth, increasing from USD 36.05 Billion in 2025 to USD 58.91 Billion by 2031, reflecting a CAGR of 8.53%. This market sector includes pharmaceutical treatments such as antibiotics, anti-inflammatories, and bronchodilators intended to manage conditions affecting the lungs and airways, including pneumonia, chronic obstructive pulmonary disease, and asthma. The primary force driving this expansion is the rising prevalence of chronic respiratory diseases that require ongoing management, a trend significantly influenced by worsening global air quality and rapid urbanization. Highlighting the severity of this issue, the Forum of International Respiratory Societies reported in 2024 that seven million deaths annually were caused by illnesses related to air pollution, emphasizing the urgent global need for effective pulmonary therapies.

Despite this strong demand, the market faces a significant obstacle in the form of antimicrobial resistance, which progressively undermines the effectiveness of standard anti-infective treatments. This biological resistance worsens clinical outcomes and compels pharmaceutical companies to navigate expensive and intricate regulatory processes to introduce new agents. Consequently, these challenges place a strain on healthcare budgets and delay the introduction of next-generation therapeutics, impeding the overall expansion of the market.

Market Driver

The rising global burden of chronic respiratory diseases acts as the primary catalyst propelling the Global Lower Respiratory Tract Therapeutics Market. This momentum is defined by the increasing prevalence of ailments such as asthma and chronic obstructive pulmonary disease (COPD), which require continuous pharmaceutical management to control symptoms and prevent exacerbations. According to the International Pharmaceutical Federation (FIP) in its 2024 'Global State of COPD Report', approximately 391 million people worldwide are currently living with COPD, establishing a vast patient population dependent on therapeutic maintenance. This demand is further intensified by environmental factors; the American Lung Association's April 2024 'State of the Air' report indicates that roughly 131 million people in the United States live in areas with unhealthy levels of particle or ozone pollution, directly fueling the need for effective respiratory treatments.

A second critical factor reshaping the market is the advancement of biologics and targeted therapeutic approaches. As traditional bronchodilators often fail to adequately treat severe cases, pharmaceutical developers are pivoting towards precision medicines and monoclonal antibodies that target specific inflammatory pathways. This shift has resulted in the successful commercialization of high-value biological agents that capture significant market share. For instance, Regeneron Pharmaceuticals reported in its 'Q3 2024 Financial Results' in October 2024 that global net sales for Dupixent, a leading biologic for respiratory conditions, increased by 23% to $3.82 billion year-over-year. This strong financial performance highlights the rapid adoption of targeted therapies and their essential role in driving future market revenue.

Market Challenge

Antimicrobial resistance represents a significant barrier to the growth of the global lower respiratory tract therapeutics market by steadily diminishing the commercial and clinical utility of existing antibiotic portfolios. As bacterial pathogens adapt to survive standard treatments, the effective lifespan of pharmaceutical products is severely curtailed, creating an unstable environment for manufacturers. This biological evolution compels companies to constantly invest in discovering new compounds to replace obsolete drugs; however, the return on investment is precarious due to the speed at which new resistance mechanisms appear. Consequently, the high risks involved in developing respiratory anti-infectives discourage sustained capital investment, slowing the overall expansion of the market.

The challenge of overcoming this resistance further restricts growth by stalling the product development pipeline. The rigorous regulatory processes required to validate new agents are both costly and time-consuming, leading to a shortage of market-ready innovations. According to the International Federation of Pharmaceutical Manufacturers & Associations in 2024, the global antibiotic pipeline included only one candidate in Phase III clinical trials targeting critical priority pathogens identified by health authorities. This lack of late-stage therapeutic options limits the industry's capacity to meet clinical demand, thereby constraining revenue potential and hampering the sector's financial progress.

Market Trends

The integration of digital health platforms and connected smart inhalers is transforming patient management by moving from reactive treatment to proactive adherence monitoring. These technologies employ sensor-enabled devices to track medication use in real-time, sending data to healthcare providers to detect non-compliance and anticipate exacerbations before they happen. This digital ecosystem enables timely interventions and provides patients with actionable insights into their respiratory health, significantly enhancing clinical outcomes. According to ResMed's 'Q2 2024 Earnings Presentation' in January 2024, the company impacted over 170 million lives with its cloud-based software and digital health products in the preceding year, demonstrating the massive scale at which connected respiratory technologies are currently influencing patient care.

Simultaneously, the market is undergoing a vital transition toward sustainable low-carbon propellant devices, driven by regulatory pressures to reduce the environmental impact of hydrofluorocarbon-based inhalers. Manufacturers are actively reformulating their portfolios to replace high-global-warming-potential propellants with eco-friendly alternatives like HFA-152a, ensuring commercial viability amidst stricter environmental mandates. This strategic shift protects product lifecycles from potential legislative bans on carbon-intensive aerosols while meeting the growing demand for environmentally responsible healthcare solutions. As noted by Pharmaceutical Technology in April 2024, Chiesi Farmaceutici has invested €350 million to develop a new inhaler propellant expected to cut the company's Scope 3 emissions by 90% compared to 2019 levels.

Key Market Players

• F. Hoffmann-La Roche Ltd.
• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A
• Pfizer Inc.
• GSK plc
• Novartis AG
• AstraZeneca inc.
• Johnson & Johnson
• Sun Pharmaceutical Industries Ltd.
• Merck & Co., Inc

Report Scope

In this report, the Global Lower Respiratory Tract Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lower Respiratory Tract Therapeutics Market, By Disease Type

• Asthma
• COPD
• Pneumonia
• Tuberculosis
• Bronchitis
• Others

Lower Respiratory Tract Therapeutics Market, By Drug Class

• Antibiotics
• Non-Steroidal Anti-Inflammatory Drugs
• Cough Suppressants
• Nasal Decongestants
• Others

Lower Respiratory Tract Therapeutics Market, By Route of Administration

• Oral
• Parenteral
• Others

Lower Respiratory Tract Therapeutics Market, By End User

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Lower Respiratory Tract Therapeutics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lower Respiratory Tract Therapeutics Market.

Available Customizations:

Global Lower Respiratory Tract Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Lower Respiratory Tract Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Type (Asthma, COPD, Pneumonia, Tuberculosis, Bronchitis, Others)
  • 5.2.2. By Drug Class (Antibiotics, Non-Steroidal Anti-Inflammatory Drugs, Cough Suppressants, Nasal Decongestants, Others)
  • 5.2.3. By Route of Administration (Oral, Parenteral, Others)
  • 5.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Lower Respiratory Tract Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type
  • 6.2.2. By Drug Class
  • 6.2.3. By Route of Administration
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Lower Respiratory Tract Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Type
      • 6.3.1.2.2. By Drug Class
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Lower Respiratory Tract Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Type
      • 6.3.2.2.2. By Drug Class
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Lower Respiratory Tract Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Type
      • 6.3.3.2.2. By Drug Class
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By End User

7. Europe Lower Respiratory Tract Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By Drug Class
  • 7.2.3. By Route of Administration
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Lower Respiratory Tract Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By Drug Class
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By End User
  • 7.3.2. France Lower Respiratory Tract Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By Drug Class
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Lower Respiratory Tract Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By Drug Class
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Lower Respiratory Tract Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease Type
      • 7.3.4.2.2. By Drug Class
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Lower Respiratory Tract Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease Type
      • 7.3.5.2.2. By Drug Class
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By End User

8. Asia Pacific Lower Respiratory Tract Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By Drug Class
  • 8.2.3. By Route of Administration
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Lower Respiratory Tract Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By Drug Class
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By End User
  • 8.3.2. India Lower Respiratory Tract Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By Drug Class
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Lower Respiratory Tract Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By Drug Class
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Lower Respiratory Tract Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease Type
      • 8.3.4.2.2. By Drug Class
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Lower Respiratory Tract Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease Type
      • 8.3.5.2.2. By Drug Class
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By End User

9. Middle East & Africa Lower Respiratory Tract Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By Drug Class
  • 9.2.3. By Route of Administration
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Lower Respiratory Tract Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By Drug Class
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Lower Respiratory Tract Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By Drug Class
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Lower Respiratory Tract Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By Drug Class
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By End User

10. South America Lower Respiratory Tract Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease Type
  • 10.2.2. By Drug Class
  • 10.2.3. By Route of Administration
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Lower Respiratory Tract Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease Type
      • 10.3.1.2.2. By Drug Class
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Lower Respiratory Tract Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease Type
      • 10.3.2.2.2. By Drug Class
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Lower Respiratory Tract Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease Type
      • 10.3.3.2.2. By Drug Class
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Lower Respiratory Tract Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. F. Hoffmann-La Roche Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Teva Pharmaceutical Industries Ltd.
• 15.3. Sanofi S.A
• 15.4. Pfizer Inc.
• 15.5. GSK plc
• 15.6. Novartis AG
• 15.7. AstraZeneca inc.
• 15.8. Johnson & Johnson
• 15.9. Sun Pharmaceutical Industries Ltd.
• 15.10. Merck & Co., Inc

16. Strategic Recommendations

17. About Us & Disclaimer